Clinical features of 5,628 primary lung cancer patients - Experience at Mayo clinic from 1997 to 2003
Clinical features of 5,628 primary lung cancer patients - Experience at Mayo clinic from 1997 to 2003
复制标题
DOI：
10.1378/chest.128.1.452
复制
发表时间：
2005-07-01
期刊：
影响因子：
9.6
通讯作者：
Deschamps, C
中科院分区：
文献类型：
--
作者：
Yang, P;Allen, MS;Deschamps, C
研究目的：为了提高目前对原发性肺癌病因和自然史的认识，需要研究大量初诊肺癌患者临床表现和预后的动态变化。在本报告中，我们介绍了患者队列的临床特征和长达 5 年的生存率。设计：我们在 1997 年至 2002 年间识别了 5,628 名原发性肺癌患者，并使用多种补充资源对他们进行了 2003 年的随访。测量和结果：在 5,628 名患者中，58% 是肺癌诊断时平均年龄为 66 岁的男性，42% 是诊断时平均年龄为 64 岁的女性。诊断时，10% 的患者年龄 < 50 岁，8% 的患者年龄 > 80 岁。 89% 的患者有吸烟史，40% 的患者在诊断时正在吸烟。按疾病阶段划分的非小细胞肺癌 (NSCLC) 患者的估计总体 5 年生存率如下： IA，66%； IB，53%；国际投资协定，42%； IIB，36%； IIIA，10%； IIIB，12%； IV，4%。小细胞肺癌患者的 5 年生存率为局限性疾病的 22%，广泛疾病的 5 年生存率为 1%。大约50%的患者参与了一项或多项研究，其中近75%的患者捐赠了生物标本用于研究。结论：与早期报告相比，这组肺癌患者的生存率略有提高，特别是低期NSCLC患者。我们的患者和生物样本资源使我们能够及时获得肺癌临床和转化研究的结果。
Study objectives: To improve the current understanding of the etiology and natural history of primary lung cancer, we need to study the dynamic changes of clinical presentation and prognosis among a large number of patients with newly diagnosed lung cancer. In this report, we present the clinical features and survival rates up to 5 years of a patient cohort.Design: We identified 5,628 primary lung cancer patients between 1997 and 2002 and followed them through 2003 using multiple, complementary resources.Measurements and results: Of the 5,628 patients, 58% were men with a mean age at lung cancer diagnosis of 66 years, and 42% were women with a mean age at diagnosis of 64 years. Ten percent were < 50 years, and 8% were > 80 years at diagnosis. A tobacco smoking history was present in 89% of patients, and 40% were smoking at the time of diagnosis. The estimated overall 5-year survival rates of patients with non-small cell lung cancer (NSCLC) by disease stage was as follows: IA, 66%; IB, 53%; IIA, 42%; IIB, 36%; IIIA, 10%; IIIB, 12%; and IV, 4%. The 5-year survival rate of patients with small cell lung cancer was 22% for limited disease and 1% for extensive disease. Approximately 50% of all patients are participants in one or more research studies, and nearly 75% of these patients have donated biological specimens for research.Conclusion: The survival rate of this cohort of lung cancer patients was slightly improved compared with earlier reports, particularly for patients with low-stage NSCLC. Our patient and biospecimen resource has enabled us to obtain timely results from clinical and translational research of lung cancer.